Johnson & Johnson's Xarelto (rivaroxaban) took a notable hit in the second quarter from the recently-implemented 70% price discount requirement for branded drugs in the Medicare Part D donut hole.
US sales for the blood thinner decreased 19
Impact Of Higher Part D Donut Hole Discounts Beginning To Show: Xarelto Sales Down 19%
Performance of Johnson & Johnson’s blockbuster cardiovascular drug is one of the first prominent examples of how the 2019 increase in the discount from 50% to 70% is playing out in the market.
More from Market Access
• By
Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.
• By
President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention.
• By
Brazil’s drug pricing authorities are planning to introduce, among other things, a new drug category for biosimilars to ensure the pricing procedures for such medicines are reflected in the official pricing framework.
• By
Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.
More from Pink Sheet
• By
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
• By
Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.
• By
The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.